![Jean-Guillaume Lafay](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Cargos activos de Jean-Guillaume Lafay
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Mablink Bioscience
![]() Mablink Bioscience Pharmaceuticals: MajorHealth Technology Mablink Bioscience is a biotechnology company based in Lyon, France that develops next-generation antibody-drug conjugates for the treatment of solid tumors. Mablink Bioscience's exclusive PSarlink™ platform is a unique stealth technology that "masks" the hydrophobicity of the cytotoxic drugs by adding a polysarcosine chain to the linker. The French company's pipeline is built on the topoisomerase-I inhibitor exatecan as a payload for current developments. Recently, the company announced the publication of a review article titled “Payload Diversification\: A Key Step in the Development of Antibody–Drug Conjugates” which reviews the history of the successes and failures in ADC payloads and takes a look at the new roads currently explored by the industry. The company was founded in 2018 by Warren Viricel and Jean-Guillaume Lafay, with Jean-Guillaume Lafay serving as CEO since then. | Director/Miembro de la Junta | - | - |
Director Ejecutivo | 01/12/2018 | - | |
Fundador | 01/12/2018 | - |
Historial de carrera de Jean-Guillaume Lafay
Estadísticas
Internacional
Francia | 2 |
Operativa
Director/Board Member | 1 |
Chief Executive Officer | 1 |
Founder | 1 |
Sectorial
Health Technology | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas privadas | 1 |
---|---|
Mablink Bioscience
![]() Mablink Bioscience Pharmaceuticals: MajorHealth Technology Mablink Bioscience is a biotechnology company based in Lyon, France that develops next-generation antibody-drug conjugates for the treatment of solid tumors. Mablink Bioscience's exclusive PSarlink™ platform is a unique stealth technology that "masks" the hydrophobicity of the cytotoxic drugs by adding a polysarcosine chain to the linker. The French company's pipeline is built on the topoisomerase-I inhibitor exatecan as a payload for current developments. Recently, the company announced the publication of a review article titled “Payload Diversification\: A Key Step in the Development of Antibody–Drug Conjugates” which reviews the history of the successes and failures in ADC payloads and takes a look at the new roads currently explored by the industry. The company was founded in 2018 by Warren Viricel and Jean-Guillaume Lafay, with Jean-Guillaume Lafay serving as CEO since then. | Health Technology |
- Bolsa de valores
- Insiders
- Jean-Guillaume Lafay
- Experiencia